Phathom Pharmaceuticals to Attend Major Investor Conferences
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing innovative treatments for gastrointestinal (GI) diseases, has announced its upcoming participation in several key investor conferences. These events are intended to boost the company’s visibility within the investment community and offer stakeholders valuable insights into its pioneering methods for addressing GI conditions.
Scheduled Conferences
The management team at Phathom Pharmaceuticals is set to engage in various activities at two prominent investor conferences in the near future. These events will facilitate one-on-one meetings and discussions centered around the company's operations and market developments.
Morgan Stanley 22nd Annual Global Healthcare Conference
This prestigious conference will take place in New York City, offering a platform for management to engage in individual discussions. The event is scheduled for early September, providing attendees the opportunity to connect with Phathom representatives to learn more about their product pipeline and strategic direction.
H.C. Wainwright 26th Annual Global Investment Conference
Shortly after the Morgan Stanley conference, Phathom will participate in a fireside chat at the H.C. Wainwright conference on a specific date in September. During this session, the management team will share insights into the company’s achievements and innovative strategies, including a Q&A segment to foster dialogue between management and attendees.
Viewing Conference Presentations
For those interested in following the discussions and presentations, Phathom Pharmaceuticals will offer a live webcast of the fireside chat, along with an archived recording. This will enable investors and industry stakeholders to stay updated on the company’s latest developments and corporate strategies.
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is committed to advancing treatments for gastrointestinal diseases. The company is particularly focused on vonoprazan, a pioneering potassium-competitive acid blocker (PCAB) that has received market approval in the U.S. as VOQUEZNA. This medication is intended for managing conditions such as heartburn associated with Non-Erosive GERD and also plays a role in treating H. pylori infections in adults. With innovative offerings like VOQUEZNA and the VOQUEZNA TRIPLE PAK, the company is leading efforts to meet unmet medical needs in the GI sector.
As Phathom Pharmaceuticals continues to grow within the biopharmaceutical industry, it emphasizes the commercialization of unique therapies that significantly benefit patients suffering from gastrointestinal disorders. The company remains dedicated to engaging with the broader investment community, showcasing its innovations, and addressing investors' interests.
Contact Information
For media inquiries, please reach out to Nick Benedetto at 1-877-742-8466 or via email at media@phathompharma.com.
For investor relations, contact Eric Sciorilli at 1-877-742-8466 or via email at ir@phathompharma.com.
Frequently Asked Questions
What is the purpose of Phathom's participation in these conferences?
Phathom aims to enhance its visibility, engage with investors, and provide updates on its innovative gastrointestinal treatments.
What key product is Phathom Pharmaceuticals developing?
The company is primarily focused on vonoprazan, a first-in-class potassium-competitive acid blocker used for various gastrointestinal conditions.
How can I access the live webcast of the fireside chat?
Phathom Pharmaceuticals will provide a link for the live webcast, which can be accessed through their website in the News & Events section.
What insights can stakeholders expect from Phathom's presentations?
Participants can expect to gain insights into the company’s pipeline, market strategies, and overall progress in the biopharmaceutical landscape.
Who should I contact for further information regarding media or investor inquiries?
For media inquiries, contact Nick Benedetto; for investor relations, reach out to Eric Sciorilli.
